Skip to main content
Top
Published in: Annals of General Psychiatry 1/2011

Open Access 01-12-2011 | Primary research

Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire

Authors: Angel L Montejo, Javier Correas Lauffer, Jesús Cuervo, Pablo Rebollo, Luis Cordero, Teresa Diez, Jorge Maurino

Published in: Annals of General Psychiatry | Issue 1/2011

Login to get access

Abstract

Background

Perception of quality of life may differ depending on the perspective. The aim of the study was to assess the psychometric properties of the Spanish version of the 'TOlerability and quality Of Life' (TOOL) questionnaire, a specific self-rated instrument to evaluate the impact of side effects of antipsychotic drugs on health-related quality of life (HRQoL). The questionnaire consists of eight items answered on a four-point Likert scale.

Methods

A psychometric study was conducted with clinically stable outpatients with schizophrenia and bipolar disorder under antipsychotic treatment. The translation and cultural adaptation of the questionnaire was performed according to international standards. Internal consistency using the Cronbach α coefficient and test-retest reliability using the intraclass correlation coefficient (ICC) was used to assess the reliability of the instrument. Patients completed generic and specific measures of quality of life and clinical severity.

Results

A total of 238 patients were analysed, with a mean age of 42 years (SD 10.9). The mean completion time was 4.9 min (SD 4.4). Internal consistency and intraclass correlation coefficient were adequate (Cronbach α = 0.757 and ICC = 0.90). Factorial analysis showed a unidimensional structure (a single eigenvalue >1, accounting for 39.1% of variance). Significant Spearman's rank correlations between the TOOL and both generic and specific measures were found. The questionnaire was able to discriminate among the Clinical Global Impression - Severity scores (Mann-Whitney U test, P < 0.001).

Conclusions

The TOOL questionnaire shows appropriate feasibility, reliability, and discriminative performance as a patient-reported outcome. TOOL constitutes a valuable addition to measure the impact of adverse events of antipsychotic drugs from the patient perspective.
Appendix
Available only for authorised users
Literature
1.
go back to reference McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008, 30: 67-76. 10.1093/epirev/mxn001.CrossRefPubMed McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008, 30: 67-76. 10.1093/epirev/mxn001.CrossRefPubMed
2.
go back to reference El-Mallakh RS, Elmaadawi AZ, Loganathan M, Lohano K, Gao Y: Bipolar disorder: an update. Postgrad Med. 2010, 122: 24-31. 10.3810/pgm.2010.07.2172.CrossRefPubMed El-Mallakh RS, Elmaadawi AZ, Loganathan M, Lohano K, Gao Y: Bipolar disorder: an update. Postgrad Med. 2010, 122: 24-31. 10.3810/pgm.2010.07.2172.CrossRefPubMed
3.
go back to reference Buckley PF: Update on the etiology and treatment of schizophrenia and bipolar disorder. CNS Spectr. 2008, 13 (Suppl 1): 3-10. Buckley PF: Update on the etiology and treatment of schizophrenia and bipolar disorder. CNS Spectr. 2008, 13 (Suppl 1): 3-10.
4.
go back to reference Edwards SJ, Smith CJ: Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009, 31: 1345-1359. 10.1016/j.clinthera.2009.07.004.CrossRefPubMed Edwards SJ, Smith CJ: Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009, 31: 1345-1359. 10.1016/j.clinthera.2009.07.004.CrossRefPubMed
5.
go back to reference Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA: Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA: Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed
6.
go back to reference Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009, 70 (Suppl 4): 1-46.PubMed Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009, 70 (Suppl 4): 1-46.PubMed
7.
go back to reference Bridle C, Palmer S, Bagnall A-M, Darba J, Duffy S, Sculpher M, Riemsma R: A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2004, 8: 1-187.CrossRef Bridle C, Palmer S, Bagnall A-M, Darba J, Duffy S, Sculpher M, Riemsma R: A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2004, 8: 1-187.CrossRef
8.
go back to reference Fonagy P, Mattheus R, Pilling S: The Mental Health Outcome Measurement Initiative: Best practice guidance for local implementation adapted from the report from the Chair of the Outcomes Reference Group. 2005, Leeds, UK: National Institute of Mental Health in England Fonagy P, Mattheus R, Pilling S: The Mental Health Outcome Measurement Initiative: Best practice guidance for local implementation adapted from the report from the Chair of the Outcomes Reference Group. 2005, Leeds, UK: National Institute of Mental Health in England
9.
go back to reference Thornicroft G, Tansella M: Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiol Psichiatr Soc. 2005, 14: 1-3.CrossRefPubMed Thornicroft G, Tansella M: Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiol Psichiatr Soc. 2005, 14: 1-3.CrossRefPubMed
10.
go back to reference Hogan T, Awad A, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983, 13: 177-183. 10.1017/S0033291700050182.CrossRefPubMed Hogan T, Awad A, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983, 13: 177-183. 10.1017/S0033291700050182.CrossRefPubMed
11.
go back to reference Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B: Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001, 50: 79-88. 10.1016/S0920-9964(00)00166-3.CrossRefPubMed Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B: Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001, 50: 79-88. 10.1016/S0920-9964(00)00166-3.CrossRefPubMed
12.
go back to reference Voruganti L, Awad A: Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002, 56: 37-42. 10.1016/S0920-9964(01)00161-X.CrossRefPubMed Voruganti L, Awad A: Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002, 56: 37-42. 10.1016/S0920-9964(01)00161-X.CrossRefPubMed
13.
go back to reference Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I: Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin. 2009, 25: 325-338. 10.1185/03007990802611919.CrossRefPubMed Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I: Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin. 2009, 25: 325-338. 10.1185/03007990802611919.CrossRefPubMed
14.
go back to reference Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987, 334: 1-100. 10.1111/j.1600-0447.1987.tb10566.x.CrossRef Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987, 334: 1-100. 10.1111/j.1600-0447.1987.tb10566.x.CrossRef
15.
go back to reference Revicki DA, Matza LS, Flood E, Lloyd A: Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics. 2005, 23: 583-94. 10.2165/00019053-200523060-00005.CrossRefPubMed Revicki DA, Matza LS, Flood E, Lloyd A: Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics. 2005, 23: 583-94. 10.2165/00019053-200523060-00005.CrossRefPubMed
16.
go back to reference Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009, 12: 536-543. 10.1111/j.1524-4733.2008.00495.x.CrossRefPubMed Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009, 12: 536-543. 10.1111/j.1524-4733.2008.00495.x.CrossRefPubMed
17.
go back to reference Lindström E, Jönsson L, Berntsson A: A patient perspective on side effects of antipsychotic therapy: the TOOL instrument. Value Health. 2009, 12: A361-CrossRef Lindström E, Jönsson L, Berntsson A: A patient perspective on side effects of antipsychotic therapy: the TOOL instrument. Value Health. 2009, 12: A361-CrossRef
18.
go back to reference Montejo AL: Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008, 18 (Suppl 2): S108-S114. 10.1016/j.euroneuro.2008.02.004.CrossRefPubMed Montejo AL: Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008, 18 (Suppl 2): S108-S114. 10.1016/j.euroneuro.2008.02.004.CrossRefPubMed
19.
go back to reference Kay SR, Fizbein A, Vital-Herne M, Fuentes LS: The Positive and Negative Syndrome Scale-Spanish adaptation. J Nerv Ment Dis. 1990, 178: 510-517.CrossRefPubMed Kay SR, Fizbein A, Vital-Herne M, Fuentes LS: The Positive and Negative Syndrome Scale-Spanish adaptation. J Nerv Ment Dis. 1990, 178: 510-517.CrossRefPubMed
20.
go back to reference Colom F, Vieta E, Martínez-Arán A, Garcia-Garcia M, Reinares M, Torrent C, Goikolea JM, Banús S, Salamero M: Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale [in Spanish]. Med Clin (Barc). 2002, 119: 366-371.CrossRef Colom F, Vieta E, Martínez-Arán A, Garcia-Garcia M, Reinares M, Torrent C, Goikolea JM, Banús S, Salamero M: Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale [in Spanish]. Med Clin (Barc). 2002, 119: 366-371.CrossRef
21.
go back to reference Lobo A, Chamorro L, Luque A, Dal-Re R, Badía X, Baro E: Validation of the Spanish versions of the Montgomery-Asberg Depression and Hamilton anxiety Rating Scales. Med Clin (Barc). 2002, 118: 493-499.CrossRef Lobo A, Chamorro L, Luque A, Dal-Re R, Badía X, Baro E: Validation of the Spanish versions of the Montgomery-Asberg Depression and Hamilton anxiety Rating Scales. Med Clin (Barc). 2002, 118: 493-499.CrossRef
22.
go back to reference Guy W: Early Clinical Drug Evaluation (ECDEU) Assessment Manual. 1976, Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch Guy W: Early Clinical Drug Evaluation (ECDEU) Assessment Manual. 1976, Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch
23.
go back to reference EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990, 16: 199-208. 10.1016/0168-8510(90)90421-9.CrossRef EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990, 16: 199-208. 10.1016/0168-8510(90)90421-9.CrossRef
24.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21: 271-292. 10.1016/S0167-6296(01)00130-8.CrossRefPubMed Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002, 21: 271-292. 10.1016/S0167-6296(01)00130-8.CrossRefPubMed
25.
go back to reference Jönsson L, Lang A, Lindström E: TOOL: Multi-attribute utility function reflecting patient experience of side effects to antipsychotic therapy. Value Health. 2009, 12: A361-CrossRef Jönsson L, Lang A, Lindström E: TOOL: Multi-attribute utility function reflecting patient experience of side effects to antipsychotic therapy. Value Health. 2009, 12: A361-CrossRef
26.
go back to reference Willke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2009, 25: 535-552. 10.1016/j.cct.2004.09.003.CrossRef Willke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2009, 25: 535-552. 10.1016/j.cct.2004.09.003.CrossRef
27.
go back to reference Barbera M, Sanjuan J, Munarriz M, Barbeŕa M, Sanjuán J, Munárriz M, Novella E, Santiago C, Simó M: Subjective experience with antipsychotics: quantitative evaluation [in Spanish]. Actas Esp Psiquiatr. 2006, 34: 287-294.PubMed Barbera M, Sanjuan J, Munarriz M, Barbeŕa M, Sanjuán J, Munárriz M, Novella E, Santiago C, Simó M: Subjective experience with antipsychotics: quantitative evaluation [in Spanish]. Actas Esp Psiquiatr. 2006, 34: 287-294.PubMed
28.
go back to reference Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousono M: Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007, 9: 215-226.PubMedCentralPubMed Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousono M: Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007, 9: 215-226.PubMedCentralPubMed
29.
go back to reference McCabe R, Saidi M, Priebe S: Patient-reported outcome in schizophrenia. Br J Psychiatry. 2007, 50: S21-S28. 10.1192/bjp.191.50.s21.CrossRef McCabe R, Saidi M, Priebe S: Patient-reported outcome in schizophrenia. Br J Psychiatry. 2007, 50: S21-S28. 10.1192/bjp.191.50.s21.CrossRef
30.
go back to reference Taksh U: A critical review of rating scales in the assessment of movement disorders in schizophrenia. Curr Drug Targets. 2006, 7: 1225-1229. 10.2174/138945006778226589.CrossRefPubMed Taksh U: A critical review of rating scales in the assessment of movement disorders in schizophrenia. Curr Drug Targets. 2006, 7: 1225-1229. 10.2174/138945006778226589.CrossRefPubMed
31.
go back to reference Konig HH, Roick C, Angermeyer MC: Validity of the EQ-5 D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007, 22: 177-187. 10.1016/j.eurpsy.2006.08.004.CrossRefPubMed Konig HH, Roick C, Angermeyer MC: Validity of the EQ-5 D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007, 22: 177-187. 10.1016/j.eurpsy.2006.08.004.CrossRefPubMed
32.
go back to reference Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J: Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res. 2006, 15: 1271-1280. 10.1007/s11136-006-0059-z.CrossRefPubMed Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J: Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res. 2006, 15: 1271-1280. 10.1007/s11136-006-0059-z.CrossRefPubMed
33.
go back to reference Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008, 6: 105-10.1186/1477-7525-6-105.PubMedCentralCrossRefPubMed Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008, 6: 105-10.1186/1477-7525-6-105.PubMedCentralCrossRefPubMed
Metadata
Title
Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire
Authors
Angel L Montejo
Javier Correas Lauffer
Jesús Cuervo
Pablo Rebollo
Luis Cordero
Teresa Diez
Jorge Maurino
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2011
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-10-6

Other articles of this Issue 1/2011

Annals of General Psychiatry 1/2011 Go to the issue